"Ocular surface squamous neoplasia" (OSSN) represents a spectrum of diseases ranging from simple dysplasia to carcinoma *in situ* to invasive squamous cell carcinoma (SCC) that involves the conjunctiva, limbus, and/or cornea.\[[@ref1]\] The treatment of OSSN depends on the tumor size and tumor extension. Topical mitomycin-C (MMC), interferon alpha-2b, and 5-fluorouracil (5-FU) have been used extensively for chemoreduction and/or as the sole treatment for noninvasive OSSN.\[[@ref2][@ref3][@ref4]\] The treatment of choice for noninvasive OSSN continues to remain wide surgical excision of the conjunctival lesion by "no touch" technique with adjunctive double freeze-thaw cryotherapy to the surgical margins and alcohol-assisted kerato-epitheliectomy for corneal involvement.\[[@ref4]\] Plaque radiotherapy is indicated in scleral-invasive SCC, whereas external beam radiation therapy has also been reported to be useful in the treatment of recalcitrant SCC of the conjunctiva.\[[@ref5][@ref6]\]

The eyes with intraocular invasion of conjunctival SCC are enucleated and in those with orbital invasion, orbital exenteration is required.\[[@ref6][@ref7]\] Since orbital extension of conjunctival SCC is relatively rare, no study has evaluated the role of systemic chemotherapy in its management. We present a case of conjunctival SCC with orbital extension, with no metastatic disease, which was treated by intravenous neoadjuvant chemotherapy (NAC) (cisplatin and 5-FU) followed by an eyelid-sparing orbital exenteration. Chemotherapy resulted in significant reduction in tumor volume, facilitating an eyelid-sparing orbital exenteration.

Case Report {#sec1-1}
===========

A 40-year-old male presented to us with a pink, fleshy mass protruding from the left palpebral fissure overhanging the lower lid, completely obscuring the left globe. Best-corrected visual acuity (BCVA) was 20/20 N6 in the right eye; however, vision could not be recorded in the left eye. There was a significant history of white nodular growth over the left ocular surface 3 years ago, which gradually and painlessly increased in size. He had undergone excision biopsy of the conjunctival lesion with an amniotic membrane grafting elsewhere 1 year ago. Details of the use of intraoperative MMC or cryotherapy were unavailable. Histopathology reports confirmed the diagnosis of SCC of the conjunctiva. The details regarding the status of tumor margins and tumor base were not available. The patient was advised to use topical MMC in the left eye (OS). However, the patient did not use any topical or systemic medication postoperatively. Over the past year, he reported a recurrence of the nodule in the left eye with rapid increase in its size, which subsequently obscured the entire left eye and presented to us with an orbital mass \[[Fig. 1a](#F1){ref-type="fig"}\]. The examination of the anterior and posterior segments of the right eye (OD) was within normal limits. BCVA OD was 20/20. A pink, fleshy mass measuring 5 cm × 3 cm × 3 cm was visible over the left ocular surface obscuring the view of the left eye. The posterior limit of the mass was not palpable. No regional lymph nodes were palpable. A clinical diagnosis of conjunctival SCC with orbital extension was made. Computed tomography of the orbits showed a well-defined, homogenous, isodense mass over the left eye extending into the inferior orbit, indenting the globe, and displacing \[[Fig. 1b](#F1){ref-type="fig"}\]. There was no evidence of bony erosion or tumor invasion into the paranasal sinuses. Incisional biopsy confirmed the diagnosis of conjunctival SCC. Owing to the large tumor size and inferior extent of the tumor, an eyelid-sparing orbital exenteration with tumor-free margins at that juncture was not feasible. A thorough systemic evaluation showed no metastatic disease. The systemic evaluation included a chest X-ray, ultrasound examination of the abdomen, liver, and renal function tests. Subsequently, NAC was planned with an aim to reduce the tumor size to facilitate an eyelid-sparing orbital exenteration.

![Response of conjunctival squamous cell carcinoma to systemic neoadjuvant intravenous chemotherapy. (a) Clinical photograph showing a pink, fleshy, mass protruding from the left palpebral fissure overhanging the lower lid completely obscuring the globe. (b) Computed tomography scan -- axial cut through the orbit showing the isodense mass lesion surrounding the left globe. (c) Clinical photograph showing reduction in the tumor size after one cycle of chemotherapy. (d) Clinical photograph showing further reduction in the tumor size after two cycles of chemotherapy. (e) Preoperative clinical photograph showing marked reduction in the tumor size after the third cycle of chemotherapy. The globe is in an elevated and abducted position owing to the tumor invading the extraocular muscles. There is evidence of diffuse conjunctival squamous cell carcinoma. Severe ectropion of the lower lid with complete tarsal show is also noted. (f) Computed tomography scan after three cycles of chemotherapy demonstrating a radiologically evident reduction in the size of the tumor around the left eye](IJO-63-927-g001){#F1}

The patient received three cycles of intravenous chemotherapy (cisplatin 150 mg and 5-FU 1000 mg daily for 3 days during each cycle) with each cycle being repeated at intervals of 3 weeks. After each cycle of chemotherapy, a reduction in the size of the orbital component of the tumor was noted \[Fig. [1c](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}\]. Throughout the chemotherapy cycles, all hematological parameters were stable, and no serious adverse effects were observed. After the third cycle, the left globe was visualized in an elevated and abducted position owing to the tumor invasion of the extraocular muscles \[[Fig. 1e](#F1){ref-type="fig"}\]. There was gross ectropion of the left lower lid with complete tarsal show. There was evidence of OS diffuse SCC involving the entire conjunctival surface and cornea. The BCVA OS was recorded as 20/40. The significant reduction in tumor size \[[Fig. 1f](#F1){ref-type="fig"}\] made an eyelid-sparing orbital exenteration possible; which the patient underwent 2 weeks after the last cycle of chemotherapy. The histopathological examination of the exenterated specimen showed a tumor mass involving the limbus, conjunctiva, parts of the cornea, and infiltrating into the adjacent orbital tissue. The lesion showed large sheets of cells with abundant cytoplasm, large vesicular nucleus, and prominent nucleoli \[[Fig. 2a](#F2){ref-type="fig"}\]. Bizarre tumor giant cells and squamous differentiation were noted, confirming the diagnosis of invasive SCC \[[Fig. 2b](#F2){ref-type="fig"}\]. There was no evidence of intraocular tumor invasion, perineural invasion, and the orbital tissue margins were clear of tumor. At last follow-up of 6 months, the socket had healed well with no local or regional tumor recurrence.

![Histopathology of exenterated specimen. (a) Photomicrograph showing conjunctival epithelium superficially and below are large sheets of cells with abundant cytoplasm, large vesicular nuclei with prominent nucleoli (H and E, ×10). (b) Photomicrograph showing hyperchromatic nucleus and bizarre tumor giant cells (H and E, ×40)](IJO-63-927-g002){#F2}

Discussion {#sec1-2}
==========

The treatment of choice for conjunctival SCC with orbital invasion is orbital exenteration. Orbital exenteration is a disfiguring surgery, which is performed mainly to achieve surgical cure for orbital malignancies or for ocular/periocular tumors with orbital extension. Based on the extent of orbital tissue removal, orbital exenteration can be divided into three categories: Subtotal, total, and extended exenteration. Based on the eyelid status, exenteration can be classified as eyelid-sparing exenteration and eyelid-sacrificing exenteration. Eyelid-sparing exenteration is a form of subtotal exenteration.\[[@ref8][@ref9]\] An eyelid-sparing exenteration heals faster since primary wound closure is achieved and is cosmetically acceptable compared to eyelid-sacrificing exenteration.

Intravenous NAC has been used to shrink large tumors and make them amenable to surgical resection.\[[@ref10][@ref11]\] Cisplatin and 5-FU have been used at the prescribed dosage as NAC in primary and metastatic head and neck malignancies.\[[@ref12][@ref13]\] These two drugs do not have overlapping toxicities, thus making it an effective combination therapy.\[[@ref12]\] Cisplatin and 5-FU have been used in combination in advanced locoregional and metastatic SCC of the skin and as a part of neo-adjuvant chemotherapy regimes in periocular and intraocular malignancies.\[[@ref14][@ref15][@ref16][@ref17]\] Therefore, given their established safety profile and anecdotal successful reports in ophthalmology, these drugs were used in the Institutional Review Board-approved protocol-based NAC regime in our patient. Based on literature review, the use of NAC for conjunctival SCC has not been reported.

Our patient, on presentation, had an orbital mass, which was causing a mechanical ectropion of the lower lid and completely obscuring it. The aim of the NAC was to reduce the tumor size such that a lid-sparing exenteration could be performed. In the absence of systemic metastasis, surgical cure from the disease would have been possible only with an eyelid-sacrificing orbital exenteration. While it did not change the surgery of choice -- orbital exenteration -- the use of NAC in this patient showed a remarkable reduction in tumor size making eyelid-sparing orbital exenteration possible with tumor-free surgical margins.

Eyelid-sparing exenteration is a less mutilating surgery with quicker recovery, lesser complications, lower postoperative morbidity, and good cosmetic outcomes by the way of facilitating the use of glued-on orbital exenteration prosthesis.\[[@ref15][@ref18]\]

Although larger studies with more number of cases are required to validate the role of systemic NAC in the management of conjunctival SCC with orbital extension, our case demonstrates that NAC may be useful in chemoreduction of the tumor prior to surgery in advanced cases of OSSN without regional or systemic metastasis.
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